Lars J. Petersen

Medical Director

2022 - Current

President, CEO

2005

ljpmedical Ltd. is a consultancy business providing strategic clinical development assistance with advanced biologics, mainly in oncology and immunology. Solid orphan drug disease knowledge. We provide evidence for risk-based clinical decisions. Successful service to more than 70 clients Worldwide. Consultant CMO with Cytovac, ROS Therapeutics, 2A Pharma, and Bainan Biotech. Consultant Medical Director with Expression Biotechnologies and Curasight.

Advisory Board Member

2020

Expert in immune-oncology, imaging, radionuclides, and theranostics.

Senior Medical Advisor

2008

Clinical development expert in KLIFO's Drug Development Council. The primary areas of expertise are oncology, immunology, dermatology, rare diseases, biomarkers, and imaging. Substantial experience in targeted therapies and immuno-oncology. Documented experience with a variety of pharmaceutical products, including monoclonal antibodies, cancer vaccines, autologous and stem cell therapies, anti-sense, and peptides. Gap analysis expert; the match of unmet medical need, clinical and regulatory development requirements, and business opportunities.

Partner

2020 - 2023

Clinical Professor (Chair)

2014 - 2021

Clinical Professor (Chair) in Nuclear Medicine. Director of research at Nuclear Medicine Aalborg. Lars J. Petersen, MD DMSc CBA is the author of 170 peer-reviewed papers in international journals of which he is first, second, or last author on >80% on the papers. He has been involved in several national and international scientific organisations, including Danish Prostate Cancer Group, EORTC Imaging Group, EORTC Oligometastatic group, EORTC Genitourinary Group, and EuroAIM Evidenced Based Imaging Group. Chair and PI of the first GCP trials with 68Ga-PSMA in Europe.

Professor

2011 - 2014

Professor at Health, Science & Technology from 2011. Moved to the Department of Clinical Medicine, when this department was launched January 1, 2013.

Chief Physician

2012 - 2021

Previously section head for nuclear medicine, since 2014 fully dedicated to research, see Clinical Professor of Nuclear Medicine.

Medical Doctor

2005 - 2011

Chief physician in nuclear medicine at Viborg Hospital. Associate Professor at the University of Aarhus.

Medical Director

2003 - 2005

Recipient of President's Award, the highest award in the company at affilate level, for outstanding performance, including sucessfull launch of Humira in Denmark.

Medical Director

2001 - 2003

Medical responsible for several early drug development programs for fully human mAbs, mainly in oncology and hematology. Designed and executed biomarker-based phase I/II trial with EGFR mAb leading directly to phase III in head and neck cancer, responsible for a 200+ patients phase II trial with IL-15 mAb in RA across five continents, first CDP in CLL for CD-20 mAb (ofatumumab, Arzerra), and served as HQ Senior Medical Advisor in medical science across most other programs.